RCP168 derived from viral macrophage inflammatory protein II is another kind of CXCR4 peptide antagonist that inhibits CXCL12- or MS-5-induced migration of Jurkat or primary CLL cells and increases the drug-induced apoptosis of leukemia cells from patients in vitro20. This evidence concerns the gene CXCR4 and leukemia.